We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Werfen Offers In-Booth Instrument Demonstrations and Educational Workshop

By LabMedica International staff writers
Posted on 22 Jul 2023

Werfen (Barcelona, Spain) is offering in-booth demonstrations of its point-of-care and laboratory instruments, reagents, and data management solutions at AACC 2023. The company is also hosting an educational workshop focusing on the prevalence and impact of pre-analytical errors in point-of-care blood gas testing. Werfen is also hosting a press conference at the AACC to introduce and explain the company’s recent acquisition of Immucor, Inc. (Norcross, GA, USA).

Werfen provides a comprehensive and integrated range of products and services. From intensive care units to operating rooms, emergency departments to interventional radiology suites and cardiac catheterization labs, and central and satellite laboratories, the company’s testing solutions are designed to deliver quality results, quickly and simply, irrespective of the setting. At AACC 2023, Werfen is offering instrument demonstrations its wide range of systems, including the ACL TOP Family 50 Series, HemoCell Specialized Lab Automation, HemosIL assays, HemoHub Intelligent Data Manager; GEM Premier 5000, GEM Premier ChemSTAT, GEM Hemochron 100, ROTEM sigma, VerifyNow, GMweb Plus 500, Aptiva, BIO-FLASH, QUANTA-Lyser, QUANTA-Link; Echo Lumena, and NEO Iris. The company is also offering a virtual reality experience featuring customized layouts for HemoCell Lab Automation.


Image: The ACL TOP Family 50 Series systems is a breakthrough in hemostasis testing (Photo courtesy of Werfen)
Image: The ACL TOP Family 50 Series systems is a breakthrough in hemostasis testing (Photo courtesy of Werfen)

At AACC 2023, senior leaders from Werfen will introduce and explain the company’s recent acquisition of Immucor, an in vitro diagnostic company with strong global leadership in the clinical areas of transfusion and transplant. With the integration of Immucor, Werfen has expanded its presence in specialized diagnostics with seven technology centers and more than 7,000 employees worldwide. The company will continue to operate directly in 34 countries, and in more than 100 territories through distributors. Most importantly, Werfen can now offer its customers an even broader portfolio of products and solutions across hospital acute care settings, and contribute to the care of more patients around the world.

Related Links:
Werfen 
Immucor, Inc. 


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
Urine Strips
11 Parameter Urine Strips

Latest AACC 2023 News

First-of-Its-Kind Single-Cell Clinical Microbiology Platform Wins 2023 Disruptive Technology Award

Ground-Breaking Phage-Based Diagnostic Kit for Laboratory Tuberculosis Testing Presented at AACC 2023

Laboratory Experts Show How They Are Leading the Way on Global Trends